Written by Allison DeAngelis
Saying it plans to launch what will likely be one of the largest clinical trials the drug industry has seen before in less than two weeks, Moderna Inc. revealed more evidence from an early-stage trial of its potential vaccine that indicated it could be successful.
Moderna (Nasdaq: MRNA) released the data from the first test of its Covid-19 vaccine after markets closed Tuesday, which included 42 of the 45 subjects originally enrolled in the NIH-led study (An additional 110 subjects were enrolled at later dates to test different age groups and doses). A Moderna spokesperson did not immediately respond to questions about why the remaining three participants’ data was not included.
Many experts criticized the company’s first data release in May, which included data from eight subjects showing the levels of antibodies that could stop Covid-19, and other data from a wider field of 25 subjects.
Read more here.